tiprankstipranks

Exact Sciences price target lowered to $70 from $75 at Wells Fargo

Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 and keeps an Overweight rating on the shares. The firm notes Exact Sciences reported a rare Q3 revenue miss and cut second half of the year guide on several factors impacting Cologuard. 2027 LRP targets are intact and Wells thinks growth will accelerate in 2025. The firm sees valuation support in low-$50s and views the 30% selloff as overdone.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue